What is OpenEvidence?
OpenEvidence is a prominent medical information platform specifically engineered for healthcare professionals. Originating from the Mayo Clinic Platform Accelerate program, the company has garnered notable attention, including recognition from the New England Journal of Medicine AI. Its services are utilized by medical practitioners across the United States, offering free and unlimited access to its comprehensive resources. The platform aims to streamline access to critical medical information, thereby enhancing clinical decision-making and patient care.
How much funding has OpenEvidence raised?
OpenEvidence has raised a total of $880M across 5 funding rounds:
Seed
$20M
Multiple Rounds
$610M
Series D
$250M
Seed (2021): $20M, investors not publicly disclosed
Series B (2025): $210M led by Thrive, Coatue, Sequoia Capital, Kleiner Perkins, Google, and Conviction
Other Financing Round (2025): $200M supported by Thrive Capital, Google, Blackstone, Coatue, Kleiner Perkins, and Sequoia Capital
Series C (2025): $200M featuring Sequoia Capital, Thrive Capital, GV, and Kleiner Perkins
Series D (2026): $250M backed by DST Global and Thrive Capital
Key Investors in OpenEvidence
Thrive Capital
Thrive Capital is an investment venture capital company that operates out of New York. Thrive Capital primarily deals in internet and software investments.
Google's mission is to organise the world's information and make it universally accessible and useful. Through products and platforms like Search, Maps, Gmail, Android, Google Play, Chrome and YouTube, Google plays a meaningful role in the daily lives of billions of people and has become one of the most widely-known companies in the world. Google is a subsidiary of Alphabet Inc.
Blackstone
Blackstone is a global investment firm that focuses on building and managing diversified asset portfolios across private equity, real estate, credit and strategic alternatives. It partners with companies, institutions and investors to create longterm value through disciplined investment strategies and operational expertise. The firm emphasises rigorous research, risk management and sustainable growth to help clients achieve their financial goals and support economic development worldwide.
What's next for OpenEvidence?
With its latest major strategic investment, OpenEvidence is poised for accelerated expansion and innovation. The substantial capital infusion is expected to fuel advancements in its platform, potentially broadening its reach and enhancing its data analytics capabilities. This significant backing suggests a strategic focus on scaling operations, further developing its AI-driven insights, and solidifying its position as a leader in the medical information technology landscape. The company's trajectory indicates a strong potential for future growth and impact within the healthcare industry.
See full OpenEvidence company page
